Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.49 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR2B | P41595 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612793 | 0.82 | SLC6A4 (0.43) | LPLLIPGAGXTHTR1AHTR2B | |
| SCHEMBL1656907 | 0.78 | LPL (0.59) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL16382817 | 0.76 | LPL (0.50) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL13960026 | 0.76 | KMT2A (0.57) | AGXTADAMTS4HTR1AHTR2BDRD2 | |
| SCHEMBL298401 | 0.76 | DGAT1 (0.72) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL120103 | 0.74 | AGXT (0.55) | AGXTADAMTS4HTR1AHTR2BDRD2 | |
| SCHEMBL1656882 | 0.74 | DGAT1 (0.46) | LPLLIPGDGAT1ADAMTS4CA1 | |
| SCHEMBL29631757 | 0.73 | LIPG (0.60) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL119892 | 0.73 | AGXT (0.54) | AGXTADAMTS4HTR1AHTR2BDRD2 | |
| SCHEMBL15481259 | 0.73 | LIPG (0.60) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923446-B2 | 3-Methyl-2-[4'-(pyridin-3-ylmethoxymethyl)-biphenyl-4-sulfonylamino]-butyric acid; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis | WYETH LLC (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1689380-A4 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | WYETH CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080311113-A1 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7390833-B2 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070225327-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7268135-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1689380-A2 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | Wyeth (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689716-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | Wyeth (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005060456-A2 | METHOD FOR TREATING ADAMTS-5-ASSOCIATE DISEASE | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061459-A1 | BIARYL SULFONAMIDES AND METHODS FOR USING SAME | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| CN-1623537-A | Biaryl sulfonamides and its using method | WYETH CORP (US) | 2005-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130973-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | LPL 885/4885LIPG 862/4885AGXT 210/4885 |
| US-20060004066-A1 | Method for treating ADAMTS-5-associated disease | ADAMTS5, ADAMTS1, ADAMTS4 | LPL 1302/4885LIPG 1566/4885AGXT 57/4885 |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | LPL 885/4885LIPG 862/4885AGXT 210/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | LPL 885/4885LIPG 862/4885AGXT 210/4885 |
| US-20080311113-A1 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE | ADAMTS5, ADAMTS1, ADAMTS4 | LPL 1302/4885LIPG 1566/4885AGXT 57/4885 |
| US-20070225327-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | LPL 885/4885LIPG 862/4885AGXT 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.